3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
7
Breast Neoplasms
7
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Erythroblastic, Acute
4
Recurrence
3
Pancreatic Neoplasms
3
Neuroblastoma
3
Melanoma
3
Medulloblastoma
3
Lymphoma, Non-Hodgkin
3
Congenital Abnormalities
3
Carcinoma, Non-Small-Cell Lung
3
Wilms Tumor
2
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Interventions
Cyclophosphamide
23
Prednisone
16
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
14
Vincristine
11
Doxorubicin
11
Etoposide
9
fludarabine phosphate
8
Whole-Body Irradiation
8
Mycophenolic Acid
7
Lenalidomide
7
Peripheral Blood Stem Cell Transplantation
6
Gemcitabine
6
Brentuximab Vedotin
6
Azacitidine
6
Alemtuzumab
6
Cyclosporine
5
Bortezomib
5
romidepsin
4
fludarabine
4
Tacrolimus
4
Rituximab
4
Methotrexate
4
Granulocyte Colony-Stimulating Factor
4
Cytarabine
4
pembrolizumab
3
denileukin diftitox
3
Transplantation
3
Dexamethasone
3
Carmustine
3
Busulfan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, T-Cell, Peripheral
×
tipifarnib
×
Clear all
NCT02464228
2024-06-26
PTCL
Kura Oncology, Inc.
Phase 2
Completed
65 enrolled
16 charts